Compare Biogen Inc (BIIB) vs Global X Robo Global Robotics & Automation ETF (ROBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Global X Robo Global Robotics & Automation ETF — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Global X Robo Global Robotics & Automation ETF trades at $84.26. Which is the better fit depends on your goals.
| BIIB | ROBO | |
|---|---|---|
Market Cap | $30.13B | — |
Sector | Health | Sector/Thematic |
52-Week High | $216.63 | $90.34 |
52-Week Low | $128.93 | $62.34 |
Enterprise Value | $37.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
ROBO, a US-listed robotics and automation ETF, trades at $84.76, up 1.56% today amid a bullish technical setup with strong moving average support. Key financial ratios are not disclosed for the ETF, but thematic focus on AI-driven robotics gains traction. Recent news highlights sector momentum and strategic rebalancing toward physical AI infrastructure.
Outlook remains positive given bullish technical signals and sector tailwinds, though high RSI suggests near-term overbought risk. Investors gain diversified exposure to robotics growth, but face volatility from cyclical end markets and valuation pressures as AI themes mature.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →
